Table 1. Patient characteristics.
| Variables | Pt 1 | Pt 2 | Pt 3 | Pt 4 | Pt 5 |
|---|---|---|---|---|---|
| Age (years) | 42 | 43 | 52 | 57 | 48 |
| Sex | F | M | F | F | F |
| Type of CCA | iCCA | iCCA | iCCA | iCCA | Gallbladder |
| NACT | Gem/Cis | Gem/Cis | Gem/Cis | Gem/Cis | Gem/Cis |
| Cycles, n | 4 | 4 | 7 | 5 | 5 |
| Stage by path | pT1N0 | ympT2B N0 M1 | ypT1N0 | ypT1N0 | ypT3N1Mx |
| MMR | Proficient | Proficient | Proficient | Proficient | Proficient |
| HER2 (by IHC) | Negative | Negative | Negative | Negative | Positive |
| Next-generation sequencing | Not performed | FGFR2 amp | TMB-4 | ROS1 mutation | CDK4 ERBB3 |
| FGFR2-RABGAP1L fusion | FGFR2 rearrangement | BRCA2 VUS | ATM | ||
| MEN1 | IKBKE amp | GLI1 | |||
| MCL1 amp | MCL1 amp | ||||
| ZNF703 amp | MDM3 amp | ||||
| PIK3c2B amp | |||||
| Response by RECIST 1.1 | PR | SD | PR | SD | SD |
| Time to recurrence (days) | 204 | 111 | 598 | 267 | 243 |
Pt, patient; M, male; F, female; CCA, cholangiocarcinoma; iCCA, intrahepatic CCA; NACT, neoadjuvant chemotherapy; Gem/Cis, gemcitabine/cisplatin; MMR, mismatch repair; IHC, immunohistochemistry; FGFR, fibroblast growth factor receptor; amp, amplification; TMB, tumor mutational burden; PR, partial response; SD, stable disease.